SUSAN STOVALL: Open Payments
NPI 1851727069 · NEW SMYRNA BEACH, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$436 in 21 payments from 9 companies in 2025. Trend: 2023 $468 · 2024 $318 · 2025 $436
Food & beverage: $436
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 4 | $87 |
| Janssen Biotech, Inc. | 4 | $85 |
| ABBVIE INC. | 4 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $71 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $32 |
| Ferring Pharmaceuticals Inc. | 1 | $24 |
| GENZYME CORPORATION | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Braintree Laboratories, Inc. | 1 | $15 |
Products named: REZDIFFRA, TREMFYA, ENTYVIO, LINZESS, DUPIXENT, REBYOTA, XIFAXAN, CREON.
Industry payments across FL — which companies pay providers there.
